Am J Transplant, Volume 16, Suppl 3 Archives - Page 144 of 180 - ATC Abstracts

2016 American Transplant Congress
Urinary Tract Infections During the First Year After Renal Transplantation: Risk Factors and Nomograms.
C. Jironda, V. López, M. Cabello, A. Duarte, C. Gutiérrez, P. Ruiz, D. Burgos, D. Hernández.
Nephrology, Regional University Hospital, Málaga, Spain.
Background: Urinary tracts infections (UTIs) are the most common infectious complications following renal transplantation (RT). The aim of this study was to evaluate the frequency…
2016 American Transplant Congress
Marked Alterations in Gene Expression in Peripheral Blood Leukocytes of Kidney Transplant (tx) Recipients Following Mycophenolic Acid (MPA) Treatment.
K. Sanghavi,¹ B. Wu,¹ C. Dorr,² A. Muthuswamy,² W. Guan,¹ D. Schladt,² R. Remmel,¹ D. Ilke,³ A. Matas,¹ A. Israni,² W. Oetting,¹ P. Jacobson.¹
¹University of Minnestoa, Minneapolis; ²MMRC, Hennepin County Medical Center, Minneapolis; ³Rho.
MPA exerts its immunosuppressive activity by inhibiting IMPDH2 enzyme, halting DNA synthesis in T and B lymphocytes. Cell culture models have shown MPA effects on…
2016 American Transplant Congress
Late Renal Allograft Rejection Is Predicted by High Intrapatient Variability of Tacrolimus Levels.
D. Goodall, M. Willicombe, A. McLean, D. Taube.
Imperial College Renal and Transplant Centre, Imperial College NHS Trust, London, United Kingdom.
IntroductionNonadherence to immunosuppressive medication is associated with rejection and graft loss. We have previously shown that intrapatient variability (IPV) of tacrolimus trough levels between 6-12…
2016 American Transplant Congress
Initial Experience with Ledipasvir-Sofosbuvir Based Therapy for Recurrent Hepatitis C After Liver Transplantation.
A. Weick, O. Sadiq, S.-M. Jafri, D. Moonka.
Henry Ford Hospital, Detroit, MI.
Objectives:Evaluate outcomes of Ledipasvir-Sofosbuvir based hepatitis C therapy in liver transplant patients at a single center.Methods:All post-liver transplant patients started on Ledipasvir-Sofosbuvir therapy between January…
2016 American Transplant Congress
Serial Peripheral Blood Mononuclear Cell Expression Profiling Reveals Inflammatory Genomic Storm Following Mechanical Circulatory Support Surgery.
G. Godoy,¹ G. Bondar,¹ A. Esmaeili,¹ E. Arellano,¹ E. Chang,¹ M. Bakir,¹ J. Chittoor,¹ R. Togashi,¹ N. Fazli,¹ C. Starling,¹ E. Oh,¹ S. Toluie,¹ Z. Yang,² D. Tran,¹ M. Cadeiras,¹ N. Wisniewski,¹ M. Kwon,¹ J. Schaenman,¹ Y. Korin,¹ M. Rosetti,¹ E. Reed,¹ M. Deng.¹
¹University of California, Los Angeles, Los Angeles, CA; ²Shanxi Medical University First Hospital, Taiyuan, Shanxi, China.
Introduction: The main cause of death in patients with Advanced Heart Failure (AdHF) is the Multi-Organ Dysfunction (MOD) Syndrome. Immune system aberrancy after Mechanical Circulatory…
2016 American Transplant Congress
Development of a Vascularized Thymus-Sternum Composite Tissue Allograft Model in Non-Human Primates.
N. O'Neill, S. Sendil, Y. Zhao, A. Hershfield, I. Tatarov, G. Braileanu, W. Hassanein, D. Parsell, A. Azimzadeh, L. Burdorf, R. Pierson, A. Nam.
Surgery, University of Maryland, Baltimore, MD.
Purpose: Vascularized composite allotransplantation (VCA) has demonstrated clinical success with standard immunosuppressive strategies in face, hand, and forearm transplantations. We developed a non-human primate model…
2016 American Transplant Congress
The Medication Level Variability Index (MLVI), a Behavioral Biomarker, Predicts Late Allograft Rejection in Pediatric Liver Transplant Recipients – A Prospective Multisite Study.
E. Shemesh,¹ J. Bucuvalas,² R. Anand,³ R. Venick,⁴ E. Alonso,⁵ J. Mitchell,³ R. Annunziato,¹ G. Mazariegos,⁶ B. Shneider.⁷
¹Mount Sinai, New York; ²Children's Hospital, Cincinnati; ³Emmes Corporation, Rockville; ⁴UCLA, Los Angeles; ⁵Lurie Children's Hospital, Chicago; ⁶Children's Hospital, Pittsburgh; ⁷Children's Hospital, Texas.
Objective: The MALT [Medication Adherence in children who had a Liver Transplant (LT), NCT-01154075, R01DK080740 (NIDDK)] multisite study prospectively evaluated a biomarker for erratic medication…
2016 American Transplant Congress
Big Data Predictive Solution to Optimize Kidney Transplant Outcome and Resource Utilization.
T. Srinivas, D. Northrup, P. Mauldin, D. Taber, Z. Su, J. Zhang, M. Daniels, W. Moran.
MUSC, Charleston.
Objective: Transplant (Tx) programs often use data in reaction to regulation vs. optimizing outcomes through data driven clinical care. Tx specific issues can detract from…
2016 American Transplant Congress
Development and Validation of a Molecular Microscope Diagnostic System (MMDx) for Heart Transplant Biopsies.
P. Halloran,¹ D. Kim,¹ A. Loupy,² J.-P. Duong Van-Huyen,² P. Bruneval,³ L. Potena,⁴ O. Leone,⁴ J. Reeve.¹
¹University of Alberta, Edmonton, Canada; ²Necker Hospital, Paris, France; ³Hopitaux de Paris, Paris, France; ⁴Bologna University, Bologna, Italy.
The diagnosis of heart transplant rejection by histology in endomyocardial biopsies (EMB) is challenging. A molecular system (MMDx) has been developed to assess both T…
2016 American Transplant Congress
Pancreas After Islet Transplantation – A Successful Treatment Option After a Failed Islet Transplant.
R. Gruessner, N. Ozden, V. Whittaker, V. Aggarwal, A. Gruessner.
Department of Surgery, SUNY Upstate Medical University, Syracuse, NY.
Introduction: Pancreas after islet (PAI) transplantation (tx) is a treatment option for patients seeking insulin independence through a whole organ transplant after a previous, failed…